THERAPEUTIC ANTIBODY DISCOVERY
When tasked with difficult therapeutic targets (cell surface, multispanning transmembrane proteins, glycoproteins, etc.) there are a few things that make Abveris uniquely equipped to deliver with the best chance of success. This includes our comprehensive services, immunization expertise, and access to leading discovery platforms.
Work at Abveris is industry-leading as well as milestone and royalty-free!
When working on unique targets, it may be difficult to find reliable reagents, namely proteins and/or cell lines. Our protein and cell line generation capabilities help to ensure that the appropriate amounts of immunization and screening materials are available. Once the project is complete, all remaining material are sent to our partners so that the materials can continue to be used as needed.
B 细胞在 Beacon 上的筛选和优化的杂交瘤开发过程使得我们能够发现大量不同的 mAb。
Next-generation sequencing efforts are accompanied by custom data reports that highlight developability concerns and deliver more value. 重组抗体的生产使我们的合作伙伴可以选择在可靠的哺乳动物细胞系中生产其首选的足够数量的抗体。
- 基于 VLP
The hyperimmune response of the DiversimAb mouse can generate appropriate titers in as little as 3 weeks, enabling rapid antibody discovery. 专有佐剂和专有免疫方案使我们的团队能够利用我们专有小鼠株的超免疫和自身免疫特性，从而有更大机会获得具有交叉反应性的多种抗体集。通过与不同的类人化平台合作，我们优化了免疫方法，以应用于治疗研发活动中常用的小鼠模型。
Abveris leverages a number of high throughput platforms for antibody screening and characterization. 这些平台包括用于高通量 ELISA 的 TECAN 系统、用于高通量细胞筛选的 iQue 流式细胞术、用于抗体动力学分析的 Carterra SPR 和 Octet 等。
- Antigen and screening materials development
- Delivery of fully human mAbs using humanized mice from Alloy and Harbour
- Proprietary, hyper-immune DiversimAb mice to generate a more diverse mAb response than wild-type mice
- Multiple immunization techniques including: DNA immunization, cell immunization, rapid protocols, adjuvants to break tolerance and assist in cross-reactivity and more
- Highly efficient B cell screening (Beacon) and hybridoma approaches
- High-throughput, industry-leading screening tools to identify ideal mAbs including the iQue flow cytometer along with the Octet and Carterra systems for affinity, activity and epitope binning analysis.
- In-house sequencing capabilities
- Scale-up and purification of mAb from hybridoma or recombinantly
ANTI-IDIOTYPE ANTIBODY DISCOVERY
At Abveris, we deliver high-quality anti-idiotype antibodies using our DiversimAbTM platform. We apply stringent, high content screening in relevant formats predictive of downstream assay success to identify quality reagents for your specific drug development assays (e.g. PK and ADA).
- High-speed offerings
- 94% success-rate delivering on our partner's goals
- Stringent screening packages
- Diverse assay candidates delivered
我们知道这些 mAb 是临床检测开发的关键工具，并且我们提供高质量试剂的速度最终会影响患者的生活。我们的团队对我们所做的工作引以为豪，并以行业领先的速度优先提供最优质的抗体，以支持您的临床试验。
CELL SURFACE TARGETING MABS
Our Secrets to Success
SELECT PROPER IMMUNOGENS
It is often challenging to present cell surface targets with proper conformation and post-translational modifications. Abveris applies innovative cell-based and DNA-based immunization protocols for cell surface immunogens to maintain the integrity of their complex structures. For certain targets and applications, recombinant proteins and peptide strategies may also provide value.
ABVERIS DIVERSIMAB™ TECHNOLOGY
The proprietary Abveris DiversimAb™ mouse provides the best in vivo option for generating monoclonal antibodies against membrane targets. DiversimAb™ technology can be applied to generate diverse panels of antibodies against tough targets, even when there are very few surface epitopes available. Abveris welcomes humanized mouse strains for fully human therapeutic antibody discovery, or knockout strains at the request of our partners.
HIGH-THROUGHPUT CELL BINDING ANALYSIS
The critical metric for success in antibody discovery for membrane targets is “on-cell binding,” thus necessitating frequent use of flow cytometry screening. The use of high-throughput flow cytometry technology unlocks the ability to screen massive panels of hybridomas with high resolution in hours instead of days.
Nature often has the superior power to utilize the diversity of immune repertoire to provide innovative insights into antibody engineering that rational design approaches may easily accomplish.
In conjunction with Abveris' proprietary hyperimmune mouse family (DievrsimAbTM Platform) and advanced screening technologies, the Hit Expansion Workflow offers opportunities to harness the power of natural repertoire diversity to expand the sequence space for rare, functionally-relevant hits, while increasing the success of antibody discovery against challenging therapeutic targets.